Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 8/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.39 |
| ▸ | HTR1D | P28221 | 10/20 | 0.38 |
| ▸ | HTR1E | P28566 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762630 | 0.78 | HTR1D (0.41) | HTR1DHTR1EHTR1ASLC6A4 | |
| SCHEMBL1762815 | 0.74 | GABRP (0.54) | CDK9 | |
| SCHEMBL9703865 | 0.73 | SLC6A4 (0.60) | HTR1DHTR1EHTR1ASLC6A4 | |
| SCHEMBL4582148 | 0.70 | HTR1D (0.41) | HTR1DHTR1A | |
| SCHEMBL1762668 | 0.66 | CSNK2A1 (0.45) | CDK9CCNT1HTR1DHTR1ADYRK1A | |
| SCHEMBL24377639 | 0.65 | CDK9 (0.44) | CDK9CCNT1HTR1DHTR1EHTR1A | |
| SCHEMBL31414538 | 0.64 | CDK9 (0.45) | CDK9CCNT1 | |
| SCHEMBL18866894 | 0.63 | CDK9 (0.50) | CDK9CCNT1 | |
| SCHEMBL21644936 | 0.62 | CDK9 (0.41) | CDK9CCNT1 | |
| SCHEMBL2522501 | 0.62 | CDK9 (0.47) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633193-B2 | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-05-19 | — | — | US | disclosed |
| US-7906528-B2 | Such as 5-(2,6-diethyl-phenyl)-1H-pyrrolo[2,3-C]pyridine, which binds C5a receptors with high affinity; for treatment of inflammatory, cardiovascular, and immune system disorders; kits | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-15 | — | — | US | disclosed |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | NEUROGEN CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2006042102-A2 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | NEUROGEN CORPORATION (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | C5AR1, C5AR2, C3AR1 | CDK9 1772/4885CCNT1 1334/4885HTR1D 324/4885 |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | C5AR1, C5AR2, C3AR1 | CDK9 1772/4885CCNT1 1334/4885HTR1D 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.